Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial
- 119 Downloads
S100B, a cytokine produced by astrocytes, has been studied as a biomarker of glial and neuronal damage in epilepsy. The present study investigated the reliability of serum S100B as a biomarker and the effect of carbamazepine and oxcarbazepine on serum S100B in patients with focal seizure.
The present randomized, open-label, active-controlled, parallel design clinical trial (NCT02705768) conducted on 60 patients with focal seizure. After recruitment, clinical evaluations were performed including Chalfont-National Hospital seizure severity scale (NHS3), Quality of Life in Epilepsy Inventory (QOLIE-31) and serum S100B was estimated. Thirty healthy individuals were recruited for evaluation of serum S100B at baseline only. After randomization, the study groups received either tablet oxcarbazepine or tablet carbamazepine. At follow-up after 2 weeks, clinical status was checked and at 4 weeks, NHS3 and QOLIE-31 were scored along with serum S100B level estimation.
Serum S100B level in patients with focal seizure increased significantly in comparison to healthy volunteers. The decrease in serum S100B was significantly higher with carbamazepine group (0.004; 95% CI 0.001–0.006; p = 0.01) over oxcarbazepine group. In logistic regression analysis, there was an increase in the log odds of 0.17 for focal seizure positivity against healthy controls if S100B level increases by 1 pg and area under curve obtained by ROC analysis was 0.96 (p < 0.001).
Serum S100B increases in the patients with focal seizure and therapy with carbamazepine can decrease serum S100B level significantly over oxcarbazepine. Serum S100B can be used as a prognostic biomarker in a focal seizure.
KeywordsFocal seizure S100B Carbamazepine Oxcarbazepine
Compliance with ethical standards
Conflicts of interest
None to declare.
The present study have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
- 5.Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T (2001) S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 18(5):491–498. https://doi.org/10.1089/089771501300227297 CrossRefPubMedGoogle Scholar
- 7.Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR (2005) Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation 65(1):49–55. https://doi.org/10.1016/j.resuscitation.2004.10.011 CrossRefPubMedGoogle Scholar
- 8.Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J (2007) Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38(9):2491–2495. https://doi.org/10.1161/STROKEAHA.106.480111 CrossRefPubMedGoogle Scholar
- 13.Steinhoff BJ, Tumani H, Otto M, Mursch K, Wiltfang J, Herrendorf G, Bittermann HJ, Felgenhauer K, Paulus W, Markakis E (1999) Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res 36(1):75–82CrossRefGoogle Scholar
- 14.Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M, Kubik A, Basta-Kaim A (2012) Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep PR 64(6):1427–1433CrossRefGoogle Scholar
- 15.Chang CC, Lui CC, Lee CC, Chen SD, Chang WN, Lu CH, Chen NC, Chang AY, Chan SH, Chuang YC (2012) Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol 12:15. https://doi.org/10.1186/1471-2377-12-15 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Lu C, Li J, Sun W, Feng L, Li L, Liu A, Li J, Mao W, Wei H, Gao L, Zhang X, Huang Z, Meng X, Wang Y (2010) Elevated plasma S100B concentration is associated with mesial temporal lobe epilepsy in Han Chinese: a case–control study. Neurosci Lett 484(2):139–142. https://doi.org/10.1016/j.neulet.2010.08.036 CrossRefPubMedGoogle Scholar
- 19.Portela LV, Tort AB, Walz R, Bianchin M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO (2003) Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy. Acta Neurol Scand 108(6):424–427CrossRefGoogle Scholar
- 20.Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685. https://doi.org/10.1111/j.1528-1167.2010.02522.x CrossRefPubMedGoogle Scholar
- 32.Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L (2000) Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Res 855(1):158–161CrossRefGoogle Scholar
- 33.Li B, Gu L, Zhang H, Huang J, Chen Y, Hertz L, Peng L (2007) Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific. Psychopharmacology 194(3):333–345. https://doi.org/10.1007/s00213-007-0853-5 CrossRefPubMedGoogle Scholar
- 34.Li B, Zhang S, Li M, Zhang H, Hertz L, Peng L (2009) Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 57(4):375–385. https://doi.org/10.1016/j.neuropharm.2009.07.004 CrossRefPubMedGoogle Scholar